Please wait while the transcript is being prepared...
0:00
Hello. This is Abdel Halim,
Director and Function Lead of
Clinical Biomarkers at
Daiichi-Sankyo Global
Pharmaceutical Company.
I'm a doctor of pharmacy,
and hold the master
degree in biochemistry,
and other master in
biochemical analysis,
and PhD in clinical biochemistry
and cancer molecular biology.
I'm triple board certified
in molecular diagnostics,
clinical chemistry,
and toxicology.
I'm a fellow of
the American Academy of
Clinical Biochemistry.
I'll be speaking today on
the potential utility,
and the challenges or biomarkers
in drug discovery
and development.
0:47
On this presentation, I'm going
to cover the main topics.
Why we need biomarkers
in drug development,
potential applications
of biomarkers
in drug discovery
and development,
and the challenges around that.
I will not be able to
cover all the challenges,
but we'll focus on major ones.
We'll provide some insight on
possible tools for
their mitigations.
1:14
Drug development
is a long process,
encompasses multiple stages from
discovery to final approval.
The entire process may
take up to 15 years,
where from every 5,000 to
10,000 chemical compounds,
only about 250 can be
good candidates for
animal experimentation.
Out to this 250,
only about five compounds
may reach the clinic
with a possibility of only
one final approved drug.
As you can see, rate of
success can be only
one in 10,000.
